The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis

Table 1

Nontumor patients vs. MM patients before treatment.

Study	Data year	Stage; I/II/III	Patients		Age (years); Control/Exp	Comparison		Test conditions and units
			Control (M/F)	Exp (M/F)		Control	Exp
Cao et al.,; 2013 [24]	2008−2011	4/8/	20 (9/11)	39 (23/16)	45/59	Healthy control	Before MM; treatment	ELISA; VEGF (pg/ml)
Li et al.,; 2016 [25]	2010−2014		30	60 (37/23)	63/67	Non-tumor; patient	Before and after treatment	ELISA; VEGF (ng/L)
Zhou et al.,; 2006 [26]	2001	1/ 2/	20	20 (15/5)	48/59	Non-tumor; patient	Before and after treatment	ELISA; VEGF (ng/L)
Cong et al., 2012 [27]	2008−2011	4/12/	26 (18/8)	23	65/68	Healthy control	Before and after treatment	ELISA; VEGF (ng/L)
Dong et al.,; 2004 [28]	2003	7/ 8/	18 (8/10)	37 (29/8)	31.3/52.5	Healthy control	Before MM; treatment	ELISA; VEGF (ng/L)

Zhang N, Shen Ti, editor. Blood disease diagnosis and efficacy standards. Version 2. Beijing: Science Press, 1998;373.376 [37]; Zhang Zhinan, Sen Ti. Blood disease diagnosis and efficacy standards. 3rd edition Beijing: Science Press. 2007, 232−235 [38]; Durie BG Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features response to treatment and survival. Cancer, 1975, 36:842−854 [39]; Blood Physicians Association, Hematology Branch of Chinese Medical Association, Multiple myeloma working group in China. China guidelines for diagnosis and treatment of multiple myeloma (revised in 2013). Chin J Int Med, 2013, 52(9):791−795 [40].